Gland Pharma Approves $21M US Investment and Board Changes
Gland Pharma Ltd 路 Change in Management 路 01 Oct 2026, 9:24 pm
Gland Pharma Approves $21M US Investment and Board Changes Gland Pharma鈥檚 board approved a USD 21 million cash investment in wholly owned subsidiary Gland Pharma USA Inc. to acquire a 60% stake in US-based Novelstar Pharma Inc. by 31st Oct'26, expanding its US market footprint. Fosun Pharma USA Inc. will hold the remaining 40% in Novelstar. Additionally, Non-Executive Non-Independent Director Wenjie Zhang resigned effective 1st Oct'26 due to preoccupations, and Xingli Wang, President of Fosun Pharma, was appointed as an Additional Director (Non-Executive Non-Independent) on the same date.
Original exchange filing (PDF)
More announcements from Gland Pharma Ltd
- Schedule of Investor Meet Intimation 路 17 Nov 2026
- Allotment of 3739 Equity Shares on exercise of ESOPs 路 16 Nov 2026
- Grant of Options to Purchase Securities 路 16 Nov 2026
- Q2FY27 Earnings Call Transcript 路 12 Nov 2026
- Gland Pharma Limited has issued Corporate Guarantee on behalf of Phixen SAS, wholly owned step down subsidiary of the Company 路 12 Nov 2026
- Appointment of Mr. Xiao Le as Chief Investment Officer at Gland Pharma International Pte. Ltd, wholly owned subsidiary of Gland Pharma Limited, effective November 09, 2026 路 09 Nov 2026
- Q2FY27 Earnings Call Recording 路 07 Nov 2026
- Q2Fy27 Investors presentation 路 06 Nov 2026
